Jeong Hyun-Ja, Na Ho-Jeong, Hong Seung-Heon, Kim Hyung-Min
Department of Pharmacology, Kyung Hee University College of Oriental Medicine, 130-701 Seoul, South Korea.
Endocrinology. 2003 Sep;144(9):4080-6. doi: 10.1210/en.2003-0115.
Mast cell accumulation can be causally related to several allergic inflammations. Previous work has demonstrated that glucocorticoids decreased tissue mast cell number, and stem cell factor (SCF)-induced migration of mast cells required p38 MAPK activation. In the present study we investigated the effects of dexamethasone on SCF-induced migration of rat peritoneal mast cells (RPMCs). SCF significantly induced the migration of RPMCs at 4 h. Dexamethasone dose-dependently inhibited SCF-induced migration of RPMCs (approximately 90.1% at 100 nM; P < 0.05). The MAPK p38 inhibitor SB203580 (20 microM) also inhibited the SCF-induced migration. The ability of SCF to enhance morphological alteration and filamentous actin formation was also abolished by treatment with dexamethasone. Dexamethasone inhibited SCF-induced p38 MAPK activation to near-basal levels and induced MAPK phosphatase-1 expression. In addition, SCF-induced inflammatory cytokine production was significantly inhibited by treatment with dexamethasone or SB203580 (P < 0.01). Our results show that dexamethasone potently regulates SCF-induced migration, p38 MAPK activation, and inflammatory cytokine production through the expression of MKP-1 protein in RPMCs. Such modulation may have functional consequences during dexamethasone treatment, especially mast cell-mediated allergic inflammation disorders.
肥大细胞的积聚可能与多种过敏性炎症存在因果关系。先前的研究表明,糖皮质激素可减少组织中肥大细胞的数量,且干细胞因子(SCF)诱导的肥大细胞迁移需要p38丝裂原活化蛋白激酶(MAPK)激活。在本研究中,我们调查了地塞米松对SCF诱导的大鼠腹膜肥大细胞(RPMC)迁移的影响。SCF在4小时时显著诱导RPMC迁移。地塞米松呈剂量依赖性抑制SCF诱导的RPMC迁移(100 nM时约为90.1%;P < 0.05)。MAPK p38抑制剂SB203580(20 microM)也抑制SCF诱导的迁移。地塞米松处理还消除了SCF增强形态改变和丝状肌动蛋白形成的能力。地塞米松将SCF诱导的p38 MAPK激活抑制至接近基础水平,并诱导丝裂原活化蛋白激酶磷酸酶-1(MAPK phosphatase-1)表达。此外,地塞米松或SB203580处理显著抑制了SCF诱导的炎性细胞因子产生(P < 0.01)。我们的结果表明,地塞米松通过RPMC中MKP-1蛋白的表达有效调节SCF诱导的迁移、p38 MAPK激活和炎性细胞因子产生。这种调节在使用地塞米松治疗期间可能具有功能影响,尤其是在肥大细胞介导的过敏性炎症疾病中。